Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.

This month's profiles: InPress Technologies, MaRVis Medical, Medherant, Molecular Assemblies, MyoPowers, Potrero Medical, Revolution Medicines, and Rivanna Medical

Molecular Assemblies Inc. aims to commercialize a “green” approach to DNA synthesis called EcoDNA. The start-up expects the biologically and enzymatically based technology to produce DNA strands up to 30 times longer than those made with the classical chemical methods.